UK markets open in 1 hour 37 minutes

WuXi Biologics (Cayman) Inc. (2269.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
13.720-0.180 (-1.29%)
As of 01:08PM HKT. Market open.
Full screen
Previous close13.900
Bid13.680 x 0
Ask13.720 x 0
Day's range13.400 - 14.000
52-week range12.900 - 55.150
Avg. volume68,998,863
Market cap57.2B
Beta (5Y monthly)0.62
PE ratio (TTM)16.53
EPS (TTM)0.830
Earnings date22 Mar 2024 - 26 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est32.08
  • PR Newswire

    WuXi Biologics Reports Solid 2023 Annual Results

    WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").

  • PR Newswire

    WuXi Biologics Named to CDP 'A List' for Water Security

    WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.

  • Bloomberg

    WuXi Biologics Options See Frenzy Amid US Policy Uncertainty

    (Bloomberg) -- Traders have piled into options on WuXi Biologics Cayman Inc. to protect against potential swings, with its sister company’s earnings in focus on Tuesday.Most Read from BloombergApple Is in Talks to Let Google Gemini Power iPhone AI FeaturesTrump Rules Out Vivek Ramaswamy as Running Mate as He Eyes New TeamNvidia Unveils Successor to Its All-Conquering AI ProcessorMusk Says His Ketamine Prescription Is in Investors’ Best InterestsEvergrande’s Alleged $78 Billion Fraud Is Among Big